Replimune Group Stock Price, News & Analysis

Replimune (NASDAQ: REPL) presented new analyses from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma patients at ASCO 2025. The combination therapy showed an objective response rate of 32.9% and complete response rate of 15.0%, with landmark overall survival rates of 75.3%, 63.3%, and 54.8% at 1, 2, and 3 years respectively. Deep/visceral injections demonstrated higher response rates (40.9-42.9%) compared to superficial-only injections (29.8%). The treatment showed effectiveness in both injected (93.6% reduction) and non-injected lesions (79.0% reduction), with robust responses in liver and lung injections. Biosafety analysis confirmed RP1's safety profile, with minimal transmission risk and effectiveness of standard disinfection procedures.

Replimune Group (NASDAQ: REPL), a clinical-stage biotech company focused on developing novel oncolytic immunotherapies, has announced its participation in the 2025 Jefferies Global Healthcare Conference. The company's management team will engage in a fireside chat on June 5, 2025, at 4:20 PM ET. Investors can access the live webcast through Replimune's website investor section, with a replay available for 30 days after the event.

Replimune Group (NASDAQ: REPL), a clinical stage biotechnology company focused on developing novel oncolytic immunotherapies, has announced two upcoming investor events. The company will host its fiscal fourth quarter and year-end 2025 earnings call on May 22, 2025, at 8:00 a.m. ET, where it will discuss financial results for the period ending March 31, 2025. Additionally, Replimune will hold an Investor Day on June 24, 2025, starting at 10:00 a.m. ET, targeted at analysts and institutional investors. Both events will be available via webcast, with replays accessible through the company's investor relations website.

Replimune Group (NASDAQ: REPL), a clinical stage biotechnology company focused on oncolytic immunotherapies, has granted inducement equity awards to 18 new non-executive employees. The awards include:

- Non-qualified stock options to purchase 21,960 shares with an exercise price of $10.01 per share - Restricted stock units representing 44,005 shares

The stock options have a 10-year term with 25% vesting after one year and the remainder vesting monthly over three years. The RSUs will vest in four annual installments starting May 15, 2026. These awards were granted under the company's 2025 Inducement Plan and approved by the compensation committee under Nasdaq Rule 5635(c)(4).

Replimune Group (NASDAQ: REPL) announced the grant of inducement equity awards to 53 newly hired non-executive employees. The compensation package includes:

• 98,450 non-qualified stock options at $7.49 per share (closing price on April 7, 2025)
• 155,875 restricted stock units (RSUs)

The stock options have a 10-year term with a 4-year vesting schedule: 25% vests after one year, followed by monthly installments over three years. RSUs vest in four annual installments starting May 15, 2026. These inducement awards, approved under Nasdaq Rule 5635(c)(4), align with the company's 2018 Equity Incentive Plan terms despite being granted outside it.

Replimune Group (NASDAQ: REPL), a clinical stage biotechnology company focused on oncolytic immunotherapies, has granted inducement equity awards to 10 newly hired non-executive employees. The compensation package includes:

• 11,085 non-qualified stock options with an exercise price of $12.29 per share (closing price on March 5, 2025)
• 22,225 restricted stock units

The stock options have a 10-year term with a 4-year vesting schedule: 25% vesting after one year, followed by monthly installments over three years. The restricted stock units vest in four approximately equal annual installments starting February 15, 2026. These inducement awards, approved under Nasdaq Listing Rule 5635(c)(4), align with the terms of the Company's 2018 Equity Incentive Plan.

Replimune Group (NASDAQ: REPL) announced key developments in its fiscal Q3 2025 report. The FDA accepted their BLA for RP1 plus nivolumab in advanced melanoma with priority review, setting a PDUFA date of July 22, 2025. The company enrolled first patients in trials for RP2 in metastatic uveal melanoma and hepatocellular carcinoma.

Financial highlights include a successful public offering raising $156.0 million net, bringing total cash position to $536.5 million as of December 31, 2024. Q3 showed increased expenses with R&D at $48.0 million (up from $42.8 million YoY) and SG&A at $18.0 million (up from $13.7 million YoY). Net loss widened to $66.3 million compared to $51.1 million in the previous year. Current cash runway extends into Q4 2026.

Replimune Group (NASDAQ: REPL) announced inducement equity awards for 34 newly hired non-executive employees. The awards include non-qualified stock options to purchase 58,240 shares at $14.25 per share (closing price on February 5, 2025) and restricted stock units (RSUs) for 116,680 shares.

The stock options have a 10-year term with a four-year vesting schedule: 25% vests after one year, with the remainder vesting monthly over three years. The RSUs vest in approximately equal annual installments starting February 15, 2026. These inducement awards, approved under Nasdaq Rule 5635(c)(4), align with the terms of the company's 2018 Equity Incentive Plan despite being granted outside it.

Replimune Group (NASDAQ: REPL) announced FDA acceptance of its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma treatment, with Priority Review status and a PDUFA date of July 22, 2025.

The FDA indicated no current plans for an advisory committee meeting and hasn't identified potential review issues. The application is supported by primary analysis data from the IGNYTE trial, which evaluated RP1 with nivolumab in anti-PD-1 failed melanoma patients. A confirmatory Phase 3 trial, IGNYTE-3, is ongoing with over 100 planned global sites.

The company recently received Breakthrough Therapy designation for this combination treatment, based on safety and clinical activity observed in the IGNYTE trial's anti-PD-1 failed melanoma cohort.